Arrowhead starts Phase I/II trial of complement-mediated disease asset

Arrowhead Pharmaceuticals has dosed the first participants in a Phase I/II clinical trial of ARO-C3 as a potential therapy for various complement-mediated diseases. ARO-C3 is an investigational ribonucleic acid interference (RNAi) treatment intended to lower the complement component 3 (C3) production. The dose-escalating, placebo-controlled trial will analyse the safety, tolerability, pharmacokinetics and pharmacodynamics of ARO-C3. It will enrol up to 24 adult healthy subjects, up to 24 adult paroxysmal nocturnal haemoglobinuria (PNH) patients as well as up to 14 adults with complement-mediated renal disease. Part 1 of the trial will have healthy subjects enrolled into four arms to assess four escalating doses of the investigational treatment. Each arm will have six participants who will be randomised to receive either one subcutaneous dose of ARO-C3 or a placebo. The open-label Part 2 of the trial will enrol patients with PNH or complement-mediated renal disease to receive ARO-C3 on the first and 85th day at one of two dose levels selected in Part 1. Analysing the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of the treatment in healthy subjects will be the primary goal of the trial. Furthermore, the primary objective will include assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of varying doses of ARO-C3 in PNH and complement-mediated renal disease patients. Arrowhead Pharmaceuticals discovery and translational medicine senior vice-president James Hamilton said:

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!